AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11207640
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GH) at 6 IU/(m(2) body surface.day)
Trial: 11207640
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GH)
Trial: 7989081
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg once daily, adjusted to 10 mg once daily if necessary after 2 weeks
Trial: 2460421
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education programs presented at three critical points: Pretreatment, Treatment Week 2, and Final Treatment Week.
Trial: 2460421
Drug: Final Treatment
RxNorm normalized name: SUSPENSION, ORAL (FINAL DOSE FORM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final Treatment Week program with pretest.
Trial: 27380862
Drug: topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical 20% vitamin C
Trial: 19023827
Drug: Conventional cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cigarettes (6-mg or 11-mg FTC tar product)
Trial: 9552785
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline 10 mL at 5 minutes after spinal injection (group A)
Trial: 9552785
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline 10 mL at 20 minutes after spinal injection (group B)
Trial: 9552785
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline 10 mL at 7 minutes after spinal injection (group D)
Trial: 9552785
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine 10 mL at 7 minutes after spinal injection (group E)
Trial: 9552785
Drug: No epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No epidural injection (group F)
Trial: 3395540
Drug: Water 100
RxNorm normalized name: water 1000 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water 100 ml administered 2 hours before operation
Trial: 30896629
Drug: Povidone-iodine suppository
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine suppository
Trial: 30896629
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no povidone-iodine suppository)
Trial: 28177167
Drug: Ketamine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.1 mg/kg)
Trial: 25488965
Drug: Treatment at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at high-accruing centers (HHACs)
Trial: 25488965
Drug: Treatment at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at historically low-accruing centers (HLACs)
Trial: 25488965
Drug: Treatment at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at HLACs with radiotherapy compliance adjustment
Trial: 19583932
Drug: Chinese compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese compound herbal medicine for reinforcing qi, activating blood circulation, expelling phlegm and dredging collaterals + simvastatin
Trial: 17081270
Drug: Efalizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (1.0 mg/kg/week for 12 weeks)
Trial: 17081270
Drug: Efalizumab re-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab re-treatment after relapse
Trial: 17081270
Drug: Efalizumab (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (initial treatment)
Trial: 31527020
Drug: MTBDRplus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTBDRplus group (discontinuation of ethambutol based on MTBDRplus assay results)
Trial: 31527020
Drug: Guideline group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline group (discontinuation of ethambutol based on phenotypic drug susceptibility test)
Trial: 18383967
Drug: Sevo-N2O group
RxNorm normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevo-N2O group inhaled 8% sevoflurane in a 60/40% mixture of oxygen and N2O
Trial: 1600930
Drug: Calcium (3
RxNorm normalized name: bicarb dialy soln 7-no pot,dex calcium (3.5 mEq/L)-magnesium (1 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (3 mg) added to meals containing iron (0.01 mg)
Trial: 31478126
Drug: Passive myofunctional
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Passive myofunctional therapy (PMFT) using an oral device nightly for 1 year
Trial: 31478126
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral device)
Trial: 29929533
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and dexmedetomidine
Trial: 29929533
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and propofol
Trial: 26178202
Drug: Computer-generated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-generated treatment preferences
Trial: 20717126
Drug: L-ornithine hydrochloride
RxNorm normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine hydrochloride (0.1 g/kg body mass)
Trial: 12485262
Drug: Adjuvant antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant antithrombotic therapy (platelet aggregation inhibitors and heparins)
Trial: 9660243
Drug: Oral food
RxNorm normalized name: Nutritional Supplement Oral Food, Solid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral food challenge
Trial: 26030651
Drug: Irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 300 mg/day for 12 months
Trial: 10984252
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at a dose of 0.6 IU/kg/day (0.2 mg/kg/day)
Trial: 10984252
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor I (IGF-I) stimulated through the GH axis
Trial: 8960082
Drug: Dobutamine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine with low dose dipyridamole
Trial: 3009633
Drug: Rhesus rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus vaccine (MMU 18006)
Trial: 10423637
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) therapy
Trial: 3303944
Drug: Single-dose piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose piperacillin (4 gm intravenously)
Trial: 3303944
Drug: Multiple-dose piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose piperacillin (three 2 gm doses intravenously 4 hours apart)
Trial: 24943065
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery for 4 weeks overnight
Trial: 24943065
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump therapy for 4 weeks overnight (control)
Trial: 18692805
Drug: Atorvastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, 20 mg daily (n = 26)
Trial: 18692805
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg daily (n = 26)
Trial: 10687834
Drug: Hormonal replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal replacement therapy (valerate estradiol‐‐2 mg/day for 21 days and cyproterone acetate‐‐1 mg/day for 10 days)
Trial: 22883122
Drug: Human aspart
RxNorm normalized name: insulin aspart, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human aspart insulin
Trial: 21396140
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g of fructose/d for 4 weeks
Trial: 21396140
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g of glucose/d for 4 weeks
Trial: 12127050
Drug: Anthrax vaccine
RxNorm normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthrax vaccine (specific lots containing squalene)
Trial: 12127050
Drug: Anthrax vaccine
RxNorm normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthrax vaccine (general AVIP participants)
Trial: 9843287
Drug: Visual cue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual cue triggering with 75 ml of contrast agent at 1.5 ml/sec
Trial: 9843287
Drug: Automated ROI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated ROI threshold triggering with 75 ml of contrast agent at 1.5 ml/sec
Trial: 9843287
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 150 ml of contrast agent at 1 ml/sec
Trial: 8078551
Drug: Cytarabine 100
RxNorm normalized name: cytarabine 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine 100 mg/m²/day for 5 days by continuous infusion
Trial: 8078551
Drug: Cytarabine 400
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 400 mg/m²/day for 5 days by continuous infusion
Trial: 8078551
Drug: Cytarabine 3
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 3 g/m² in a 3-hour infusion every 12 hours on days 1, 3, and 5
Trial: 30787295
Drug: Intradermal injections
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injections of modified mRNA encoding VEGF‐A
Trial: 28106245
Drug: Metformin (1,700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,700 mg/day) + active lifestyle intervention
Trial: 28106245
Drug: Metformin (1,700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,700 mg/day) alone
Trial: 24122176
Drug: Acetaminophen (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1.5 g)
Trial: 17427914
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) for chronic nightmares
Trial: 16268466
Drug: Ximelagatran (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (24 mg twice daily)
Trial: 7564328
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Ro 40‐5967 in 60 min
Trial: 7564328
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Ro 40‐5967 in 30 min
Trial: 7564328
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Ro 40‐5967 in 15 min
Trial: 7564328
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg Ro 40‐5967 in 30 min (two simultaneous doses of 40 mg)
Trial: 7564328
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg Ro 40‐5967 in 30 min (one arm)
Trial: 1682645
Drug: Pseudomonas aeruginosa
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas aeruginosa octavalent O‐polysaccharide‐toxin A conjugate vaccine
Trial: 6185060
Drug: Loperamide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide at a dose of 0.2 mg/kg/day
Trial: 30592390
Drug: Single-dose umbilical
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose umbilical cord-derived mesenchymal stromal cells (UC-MSCs) at baseline (20 × 10^6)
Trial: 25256258
Drug: Abediterol 25
RxNorm normalized name: Abediterol
DrugBank: Abediterol (DB12100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abediterol 25 μg
Trial: 17241864
Drug: Reducing peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reducing peginterferon alfa-2a dose to < or =60%
Trial: 17241864
Drug: Full-dose peginterferon
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose peginterferon alfa-2a (> or =98%) with ribavirin dose reduced to < or =60%
Trial: 17241864
Drug: Full-dose peginterferon
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose peginterferon alfa-2a with prematurely discontinued ribavirin
Trial: 7697848
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg rPF4
Trial: 7697848
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg rPF4
Trial: 7697848
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg rPF4
Trial: 7697848
Drug: 5.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg rPF4
Trial: 7697848
Drug: rPF4 administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rPF4 administration
Trial: 29559423
Drug: Methylphenidate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10 mg)
Trial: 29559423
Drug: Galantamine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (16 mg)
Trial: 28301264
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with a median prescription dose of 70 Gy
Trial: 28301264
Drug: Mean heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean heart dose
Trial: 25935340
Drug: Preoperative hyperosmotic
RxNorm normalized name: HYPEROSMOTIC LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hyperosmotic treatment with sodium chloride 5% ophthalmic ointment (Muro‐128)
Trial: 25935340
Drug: Control eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control eyes (no hyperosmotic treatment)
Trial: 23806384
Drug: Dietary nitrate
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary nitrate (250 ml beetroot juice)
Trial: 23806384
Drug: Potassium nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium nitrate capsules (KNO3, 8 mmol)
Trial: 21457238
Drug: telcagepant +
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant + ibuprofen 280 mg + ibuprofen 400 mg
Trial: 21457238
Drug: telcagepant +
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant + acetaminophen 280 mg + acetaminophen 1000 mg
Trial: 17702703
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus an additional session of standing practice
Trial: 15383482
Drug: IV tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tissue plasminogen activator (tPA) if treatment is initiated within 3 h of symptom onset
Trial: 15383482
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy for patients with extensive and clearly identifiable hypodensity on CT
Trial: 15383482
Drug: Full-dose anticoagulation
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose anticoagulation with IV or subcutaneous heparins or heparinoids
Trial: 15383482
Drug: Early aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early aspirin therapy, 160 to 325 mg qd
Trial: 15383482
Drug: Prophylactic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prophylactic low-dose subcutaneous heparin or low molecular weight heparins or heparinoids for AIS patients with restricted mobility
Trial: 15383482
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression devices or elastic stockings for patients with contraindications to anticoagulants
Trial: 15383482
Drug: Antiplatelet agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agent treatment (including aspirin, combination of aspirin and extended-release dipyridamole, or clopidogrel) for noncardioembolic stroke or TIA
Trial: 15383482
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin and extended-release dipyridamole over aspirin
Trial: 15383482
Drug: Clopidogrel over
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel over aspirin for noncardioembolic stroke or TIA
Trial: 15383482
Drug: Clopidogrel for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel for patients allergic to aspirin
Trial: 15383482
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral anticoagulation for patients with atrial fibrillation and a recent stroke or TIA
Trial: 15383482
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin or low molecular weight heparin for patients with venous sinus thrombosis during the acute phase
Trial: 11422739
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion with AT1R blockade
Trial: 9865645
Drug: Ciprofloxacin hydrochloride,
RxNorm normalized name: Ciprofloxacin Hydrochloride, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin hydrochloride, 400 mg every 12 hours, and metronidazole hydrochloride, 500 mg every 6 hours
Trial: 9865645
Drug: Gentamicin sulfate,
RxNorm normalized name: Gentamicin Sulfate, Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin sulfate, 2.5 mg/kg every 12 hours, and metronidazole hydrochloride, 500 mg every 6 hours
Trial: 7878282
Drug: Isosorbide-5-mononitrate (IS-5-MN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 40 mg/12 hours
Trial: 7878282
Drug: Isosorbide-5-mononitrate (IS-5-MN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 40 mg/8 hours
Trial: 25888180
Drug: Antibiotic checklist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic checklist implementation
Trial: 22859496
Drug: 180 μg
RxNorm normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 μg PegIFN for 48 weeks
Trial: 22859496
Drug: 180 μg
RxNorm normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks
Trial: 22859496
Drug: 180 μg
RxNorm normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 μg PegIFN plus lamivudine for 48 weeks then 135 μg PegIFN for 48 weeks
Trial: 20234035
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (2.25 g) plus policosanol (10 mg) for 21 days
Trial: 17823447
Drug: Low-fat fermented
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat fermented milk enriched with 0.8 g plant sterol (PS) ester per portion, consumed daily for 6 weeks
Trial: 17823447
Drug: Control low-fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control low-fat fermented milk, consumed daily for 6 weeks
Trial: 11522565
Drug: High-fiber, high-fruit-and-vegetable,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber, high-fruit-and-vegetable, low-fat diet (4.30 g/MJ fiber, 0.84 servings/MJ fruit and vegetables, 20% of energy from fat)